Prolonged in-vivo half-life of factor VIIa by fusion to albumin

Summary For the treatment of haemophilia patients with inhibitors, recombinant factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy. However, the short in-vivo half-life of approximately 2.5 hours makes multiple injections...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2008-04, Vol.99 (4), p.659-667
Hauptverfasser:	Weimer, Thomas, Wormsbächer, Wilfried, Kronthaler, Ulrich, Lang, Wiegand, Liebing, Uwe, Schulte, Stefan
Format:	Artikel
Sprache:	eng
Schlagworte:	albumin fusion Animals Base Sequence Biological and medical sciences Blood Coagulation, Fibrinolysis and Cellular Haemostasis Blood coagulation. Blood cells Coagulants - pharmacokinetics Coagulants - therapeutic use coagulation DNA, Recombinant - genetics Factor VIIa - genetics Factor VIIa - pharmacokinetics Factor VIIa - therapeutic use Fundamental and applied biological sciences. Psychology FVIIa Half-Life Hematologic and hematopoietic diseases Hemophilia A - blood Hemophilia A - drug therapy Hemostasis - drug effects Humans In Vitro Techniques Medical sciences Molecular and cellular biology Platelet diseases and coagulopathies Protein Binding Protein Engineering Rats Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - pharmacokinetics Recombinant Fusion Proteins - therapeutic use Recombinant Proteins - genetics Recombinant Proteins - pharmacokinetics Recombinant Proteins - therapeutic use rVIIa-FP Serum Albumin - genetics Serum Albumin - pharmacokinetics Serum Albumin - therapeutic use Surface Plasmon Resonance Thrombelastography Thromboplastin - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!